Previous 10 | Next 10 |
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference PR Newswire EMERYVILLE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and ...
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and ...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-10 15:35:40 ET Summary Dynavax's net income dropped by 97% in Q2, 2023 compared to the previous year, but analysts praised management's performance. The company's HEPLISAV-B vaccine has exceeded expectations and is expected to contribute to future revenue growth. Dynav...
2023-08-04 01:00:34 ET Image source: The Motley Fool. Dynavax Technologies (NASDAQ: DVAX) Q2 2023 Earnings Call Aug 03, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Dynavax Technologies (DVAX) Q2 2023 Earnings Ca...
2023-08-03 19:25:22 ET Dynavax Technologies Corporation (DVAX) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Paul Cox - VP of IR and Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Jan...
2023-08-03 16:36:01 ET Dynavax press release ( NASDAQ: DVAX ): Q2 GAAP EPS of $0.03 beats by $0.12 . Revenue of $60.25M (-76.5% Y/Y) beats by $11.87M . 2023 FINANCIAL GUIDANCEFull year 2023 financial guidance has been revised to consist of the following expec...
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire Generated record quarterly HEPLISAV-B ® vaccine net product revenue of $56 million , a 73% year-over-year increase Full year HEPLISAV-B net pr...
2023-07-27 08:53:28 ET Summary Dynavax Technologies specializes in innovative vaccines, including their flagship product, HEPLISAV-B, a Hepatitis B vaccine, and their CpG 1018 adjuvant, used in several COVID-19 vaccines. Despite lower total revenues YoY, HEPLISAV-B sales are on th...
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 PR Newswire EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...